000282684 001__ 282684
000282684 005__ 20240917101821.0
000282684 0247_ $$2doi$$a10.1016/j.canep.2023.102449
000282684 0247_ $$2pmid$$apmid:37679266
000282684 0247_ $$2ISSN$$a1877-7821
000282684 0247_ $$2ISSN$$a1877-783X
000282684 0247_ $$2altmetric$$aaltmetric:153926442
000282684 037__ $$aDKFZ-2023-01830
000282684 041__ $$aEnglish
000282684 082__ $$a610
000282684 1001_ $$aTichanek, Filip$$b0
000282684 245__ $$aSteady survival improvements in soft tissue and bone sarcoma in the Nordic countries through 50 years.
000282684 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2024
000282684 3367_ $$2DRIVER$$aarticle
000282684 3367_ $$2DataCite$$aOutput Types/Journal article
000282684 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1726560304_13460
000282684 3367_ $$2BibTeX$$aARTICLE
000282684 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282684 3367_ $$00$$2EndNote$$aJournal Article
000282684 500__ $$a#LA:C020# / 2024 Oct;92:102449
000282684 520__ $$aSarcomas are rare cancers with many subtypes in soft tissues, bone and cartilage. International survival trends in these cancers are not well known. We present 50-year survival trends for soft tissue sarcoma (STS) and bone sarcoma (BS) in Denmark (DK), Finland (FI), Norway (NO) and Sweden (SE).Relative 1-, 5/1 conditional- and 5-year survival data were obtained from the NORDCAN database for years 1971-20. We additionally estimated annual changes in survival rates and determined significant break points.In the last period, 2016-20, 5-year survival in STS was best for NO men (74.6%) and FI women (71.1%). For the rarer BS, survival rates for SE men (72.0%) and DK women (71.1%) were best. Survival in BS was lower than that in STS in 1971-75 and the difference remained in 2016-20 for men, but for women the rates were almost equal. Sex- and country-specific differences in survival in STS were small. The 50-year improvement in 5-year survival in STS was highest in NO men, 34.0 % units and FI women, 30.0 % units. The highest improvements in BS were in SE men 26.2 % units and in FI women 29.2 % units.The steady development in survival over the half century suggests contribution by stepwise improvements in diagnostics, treatment and care. The 10-15% mortality in the first year probably indicates diagnostic delays which could be improved by organizing patient pathways for aggressive rare diseases. Early diagnosis would also reduce metastatic disease and breakthroughs in treatment are a current challenge.
000282684 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000282684 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000282684 650_7 $$2Other$$aConditional survival
000282684 650_7 $$2Other$$aDiagnostics
000282684 650_7 $$2Other$$aIncidence
000282684 650_7 $$2Other$$aRelative survival
000282684 650_7 $$2Other$$aTreatment
000282684 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b1$$udkfz
000282684 7001_ $$aHemminki, Otto$$b2
000282684 7001_ $$aHemminki, Akseli$$b3
000282684 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b4$$eLast author$$udkfz
000282684 773__ $$0PERI:(DE-600)2498032-8$$a10.1016/j.canep.2023.102449$$gp. 102449 -$$p102449$$tCancer epidemiology$$v92$$x1877-7821$$y2024
000282684 909CO $$ooai:inrepo02.dkfz.de:282684$$pVDB
000282684 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000282684 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000282684 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000282684 9141_ $$y2023
000282684 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-18
000282684 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-18
000282684 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-18
000282684 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-22
000282684 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-22
000282684 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-22
000282684 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-22
000282684 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-22
000282684 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER EPIDEMIOL : 2022$$d2023-08-22
000282684 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-22
000282684 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-22
000282684 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-22
000282684 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-22
000282684 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000282684 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000282684 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000282684 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x2
000282684 980__ $$ajournal
000282684 980__ $$aVDB
000282684 980__ $$aI:(DE-He78)B062-20160331
000282684 980__ $$aI:(DE-He78)HD01-20160331
000282684 980__ $$aI:(DE-He78)C020-20160331
000282684 980__ $$aUNRESTRICTED